United Therapeutics Corporation $UTHR Shares Acquired by Merit Financial Group LLC

Merit Financial Group LLC increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 56.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,416 shares of the biotechnology company’s stock after acquiring an additional 2,672 shares during the quarter. Merit Financial Group LLC’s holdings in United Therapeutics were worth $3,109,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Chung Wu Investment Group LLC purchased a new position in United Therapeutics during the 2nd quarter worth $29,000. WealthCollab LLC boosted its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. grew its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in United Therapeutics in the 2nd quarter valued at about $53,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. UBS Group boosted their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Stock Up 1.9%

NASDAQ:UTHR opened at $496.72 on Friday. The firm’s fifty day simple moving average is $478.35 and its 200-day simple moving average is $394.39. The stock has a market cap of $21.39 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 4.68 and a beta of 0.84. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter last year, the business earned $6.39 earnings per share. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, Director Louis W. Sullivan sold 5,950 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $512.13, for a total value of $3,047,173.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 2,000 shares of United Therapeutics stock in a transaction on Friday, December 19th. The stock was sold at an average price of $507.07, for a total value of $1,014,140.00. Following the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $65,919.10. This represents a 93.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 618,464 shares of company stock worth $287,887,010. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.